[go: up one dir, main page]

ATE495739T1 - Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa - Google Patents

Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa

Info

Publication number
ATE495739T1
ATE495739T1 AT04782161T AT04782161T ATE495739T1 AT E495739 T1 ATE495739 T1 AT E495739T1 AT 04782161 T AT04782161 T AT 04782161T AT 04782161 T AT04782161 T AT 04782161T AT E495739 T1 ATE495739 T1 AT E495739T1
Authority
AT
Austria
Prior art keywords
methods
carbidopa
levodopa
pharmaceutical compositions
compositions
Prior art date
Application number
AT04782161T
Other languages
English (en)
Inventor
Julius Remenar
Orn Almarsson
Anthony Meehan
Zhong Zhang
Original Assignee
Transform Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transform Pharmaceuticals Inc filed Critical Transform Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE495739T1 publication Critical patent/ATE495739T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT04782161T 2003-08-29 2004-08-26 Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa ATE495739T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US49925603P 2003-08-29 2003-08-29
US50555103P 2003-09-24 2003-09-24
US55986404P 2004-04-06 2004-04-06
US58644204P 2004-07-08 2004-07-08
PCT/US2004/027607 WO2005023185A2 (en) 2003-08-29 2004-08-26 Pharmaceutical compositions and method of using levodopa and carbidopa

Publications (1)

Publication Number Publication Date
ATE495739T1 true ATE495739T1 (de) 2011-02-15

Family

ID=34280054

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04782161T ATE495739T1 (de) 2003-08-29 2004-08-26 Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa

Country Status (10)

Country Link
US (1) US20050070608A1 (de)
EP (1) EP1670450B8 (de)
JP (1) JP5160786B2 (de)
AT (1) ATE495739T1 (de)
AU (1) AU2004270174B2 (de)
CA (1) CA2536175C (de)
DE (1) DE602004031134D1 (de)
HK (1) HK1085140A1 (de)
MX (1) MXPA06002344A (de)
WO (1) WO2005023185A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
US20080299204A1 (en) * 2005-06-23 2008-12-04 Spherics, Inc. Dosage forms for movement disorder treatment
US20070027216A1 (en) * 2005-07-15 2007-02-01 Bridget Larson Novel hydrochloride salts of levodopa
AU2006327254A1 (en) * 2005-12-20 2007-06-28 Cereuscience Ab Method and composition for treating and diagnosing restless legs syndrome
AU2007338631A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
JP5631734B2 (ja) * 2007-04-06 2014-11-26 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 流体薬物を供給するためのシステム及び方法
AU2014202306B2 (en) * 2007-12-28 2016-09-08 Impax Laboratories, Llc Controlled release formulations of levodopa and uses thereof
KR101752080B1 (ko) * 2007-12-28 2017-06-28 임팩스 라보라토리즈, 인코포레이티드 레보도파 방출 제어형 제제 및 이의 용도
WO2010134074A1 (en) * 2009-05-19 2010-11-25 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
WO2011032929A1 (en) * 2009-09-18 2011-03-24 Sanofi-Aventis (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
WO2013035053A2 (en) * 2011-09-09 2013-03-14 Kareus Therapeutics, Sa Novel conjugation-facilitated transport of drugs across blood brain barrier
EP3054929B1 (de) 2013-10-07 2020-08-05 Impax Laboratories, LLC Mukoadhäsive levodopa-formulierungen mit gesteuerter freisetzung und/oder levodopa-ester und verwendungen davon
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
WO2015136538A1 (en) * 2014-03-13 2015-09-17 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US10258585B2 (en) * 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
CA3175785A1 (en) 2014-09-04 2016-03-10 Intrance International Ab Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof
MX2017005236A (es) 2014-10-21 2017-07-26 Abbvie Inc Profarmacos de carbidopa y l-dopa y metodos de uso.
BR112017023674A2 (pt) 2015-05-06 2018-07-17 Synagile Corporation suspensões farmacêuticas contendo partículas de fármaco, dispositivos para sua administração, e métodos de seu uso
WO2017039525A1 (en) 2015-09-04 2017-03-09 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
AU2017250002B2 (en) * 2016-04-11 2022-12-22 University Of Canberra Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
US20190224220A1 (en) * 2016-04-20 2019-07-25 Abbvie Inc. Carbidopa and L-Dopa Prodrugs and Methods of Use
CA3065990A1 (en) * 2017-06-05 2018-12-13 Dizlin Pharmaceuticals Ab Levodopa infusion solution
JP2021509676A (ja) * 2018-01-05 2021-04-01 インペル ニューロファーマ インコーポレイテッド 精密嗅覚装置によるレボドパ粉末の鼻腔内送達
AU2019237857B2 (en) 2018-03-23 2024-11-21 Lobsor Pharmaceuticals Aktiebolag Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
US11517548B2 (en) 2018-07-19 2022-12-06 Impel Pharmaceuticals Inc. Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease
WO2020102628A1 (en) 2018-11-15 2020-05-22 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
CA3196650A1 (en) 2020-12-22 2022-06-30 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928431A (en) * 1972-07-14 1975-12-23 Medica Ab Oy Method of isolating L-dopa from a aqueous solution thereof
US4771073A (en) * 1985-12-30 1988-09-13 Merck & Co., Inc. Rectally absorbable form of L-dopa
DE3779500T2 (de) * 1986-06-10 1993-01-21 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US4829875A (en) * 1988-09-12 1989-05-16 Queen's University At Kingston Over-centre locking tool
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
US5607969A (en) * 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
US5881926A (en) 1993-03-11 1999-03-16 Taro Pharmaceutical Industries, Ltd. Pharmaceutical compositions in semisolid form and a device for administration thereof
US6166081A (en) * 1997-10-09 2000-12-26 Kushnir; Moshe Methods and apparatus for treatment of Parkinson's disease
HUP0104586A3 (en) * 1998-11-10 2002-12-28 Teva Pharma Dispersible compositions containing l-dopa ethyl ester and process for their preparation
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
IL162294A0 (en) * 2001-12-19 2005-11-20 Alza Corp Formulation & dosage form for the controlled delivery of therapeutic agents

Also Published As

Publication number Publication date
US20050070608A1 (en) 2005-03-31
DE602004031134D1 (de) 2011-03-03
AU2004270174A1 (en) 2005-03-17
AU2004270174B2 (en) 2010-05-20
CA2536175A1 (en) 2005-03-17
CA2536175C (en) 2013-05-28
EP1670450B8 (de) 2011-03-23
EP1670450B1 (de) 2011-01-19
JP5160786B2 (ja) 2013-03-13
WO2005023185A3 (en) 2005-05-19
WO2005023185A2 (en) 2005-03-17
MXPA06002344A (es) 2006-05-19
EP1670450A4 (de) 2008-08-27
HK1085140A1 (en) 2006-08-18
EP1670450A2 (de) 2006-06-21
JP2007504143A (ja) 2007-03-01

Similar Documents

Publication Publication Date Title
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
CY1111263T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE521357T1 (de) Verfahren zur behandlung von hepatitis
EA200870019A1 (ru) Лактамовые соединения и способы их применения
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
DE502004012196D1 (de) Verwendung von isorhamnetin zur behandlung von depressiven verstimmungen und erkrankungen
DE60137506D1 (de) Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE395055T1 (de) Pharmazeutische zusammensetzung zur behandlung von hyperhomocysteinämie
ATE318594T1 (de) Verwendung von treosulfan und derivaten davon zur behandlung der multiplen sklerose
DE602005018941D1 (de) Verwendung von winterbohnenkraut (satureja montana) oder seinen extrakten zur herstellung von medikamenten zur behandlung von vorzeitiger ejakulation
DE602006004568D1 (de) Verwendung von phenylacetylderivaten zur herstellung eines arzneimittels zur behandlung der von-hippel-lindau-erkrankung
ATE454144T1 (de) Behandlung von malignen neoplasien
ATE425755T1 (de) 4-aminophenyl-morpholinon-derivate zur behandlung von hepatitis c
TW200615000A (en) Use of arginase for the treatment of hepatitis
ATE418982T1 (de) Verwendung von poly-aminopyrrolcarboxamide in kombination mit einem cyclodextrin zur prophylaxe und behandlung von parasitose bei tieren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1670450

Country of ref document: EP